PTC Therapeutics (PTCT) Tmuɣli n wazal
Ṛṛbem n lḥedd$62.67Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel+0.61%
Asnulfu n AI: PTCT
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
PTC Therapeutics, Inc. provides biopharmaceutical products. The company develops oral and small-molecule drugs for the treatment of genetic, oncological, and infectious diseases. PTC Therapeutics operates in the United States.
